 IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin POMC, including PCSK1, deficiency or biallelic leptin receptor LEPR deficiency in adults and children six years of age and above 